Ciprofloxacin and dexamethasone NDC 70244-033

NDC codes

FDA NDC Directory

Product NDC (as listed)70244-033Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70244-0033Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70244-033-01	70244003301	1 BOTTLE, DROPPER in 1 CARTON (70244-033-01) / 7.5 mL in 1 BOTTLE, DROPPERMarketed from Apr 16, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ciprofloxacin and dexamethasone
Generic name (nonproprietary): ciprofloxacin and dexamethasone
Active ingredients: Ciprofloxacin hydrochloride — 3 mg/mLDexamethasone — 1 mg/mL
Dosage form: Suspension/ drops
Route: Auricular (Otic)
Labeler: Sentiss Pharmaceuticals LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215768
Marketing start: Apr 16, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)Cytochrome P450 1A2 Inhibitors (Mechanism)Fluoroquinolones (Chemical structure)
Identifiers: Product ID 70244-033_4f98e817-83be-84c5-e063-6294a90ada18SPL ID 4f98e817-83be-84c5-e063-6294a90ada18SPL set ID 355fa56f-d7a8-444e-9dec-8ba1fa4ab0d8RxCUI 403908UNII 4BA73M5E37, 7S5I7G3JQL
Pharmacologic class: Corticosteroid; Fluoroquinolone Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N470244003301 followed by a unit qualifier and the quantity

Package 70244-0033-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 16, 2026.

Indications (excerpt from the label)

Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below:(1) • Acute Otitis Media (/\OM) in pediatric patients (age 6 months and older with tympanostomy tubes due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa (1) Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa .(1) Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension is a combination of ciprofloxacin, a fluo…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215768

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215768
Product	Strength	Form · route	Labeler	Product NDC
Ciprofloxacin and dexamethasone	Ciprofloxacin hydrochloride 3 mg/mL; Dexamethasone 1 mg/mL	Suspension/ dropsAuricular (Otic)	ARMAS PHARMACEUTICALS INC.	72485-625
Ciprofloxacin and dexamethasone	Ciprofloxacin hydrochloride 3 mg/mL; Dexamethasone 1 mg/mL	Suspension/ dropsAuricular (Otic)	Redpharm Drug	67296-1943